Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

• Main Authors: Katalin Pungor (Author), Vasilis P. Bozikas (Author), Robin Emsley (Author), Pierre-Michel Llorca (Author), Srihari Gopal (Author), Maju Mathews (Author), Annette Wooller (Author), Paul Bergmans (Author)
• Format: Book
• Published: SAGE Publishing, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis...